Compare Citius Pharmaceuticals Inc (CTXR) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Rockwell Automation — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Rockwell Automation trades at $447.95 (market cap $48.33B). The key difference: Rockwell Automation is far larger — about 2580.4× Citius Pharmaceuticals Inc's market cap, and Rockwell Automation pays a 1.27% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ROK | |
|---|---|---|
Market Cap | $18.73M | $48.33B |
Sector | Health | Industrials |
52-Week High | $1.82 | $495.08 |
52-Week Low | $0.48 | $333.75 |
Enterprise Value | $14.95M | $51.46B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Rockwell Automation (ROK) trades at $441.04, down 0.17% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 49.09% gross margin and 13.38% net income margin, but elevated valuation ratios like a P/E of 41.3 suggest premium pricing. Q3 2026 results exceeded expectations, driven by organic sales growth and margin expansion, prompting raised full-year guidance.
The outlook is mixed: analyst consensus leans bullish with a $480.25 price target (30% buy ratings), but technical weakness and high valuation pose near-term risks. Key catalysts include sustained automation demand and cost management, while inflation and competitive pressures remain headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
